From: Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
Characteristics | Unadjusted OR (95% CI) | Model I | Model II | ||
---|---|---|---|---|---|
Adjusted OR (95% CI) | Attributable risk | Adjusted OR (95% CI) | Attributable risk | ||
Male | 0.598 (0.212–1.688) | 0.251 (0.060–1.048) | 0.266 (0.065–1.084) | ||
Age ≥ 65 | 2.623 (0.902–7.633) | 3.198 (1.023–9.997)* | 68.7 | 3.540 (1.123–11.164)* | 71.8 |
BSA ≥ 1.6 | 1.398 (0.460–4.244) | 3.545 (0.787–15.972) | 3.188 (0.723–14.053) | ||
PPI | 3.528 (0.984–12.651) | 3.529 (0.916–13.595) | |||
H2 blocker or PPI | 3.083 (1.056–9.000)* | 3.454 (1.114–10.713)* | 71.0 |